New Treatments for the Carcinoid Syndrome.

作者: Paul Benjamin Loughrey , Dongyun Zhang , Anthony P. Heaney

DOI: 10.1016/J.ECL.2018.04.014

关键词: MedicineCancer researchCarcinoid syndromeSunitinibEmbolizationNeuroendocrine tumorsRadionuclide therapySymptom reliefEverolimusTelotristat Etiprate

摘要: Neuroendocrine tumors, including carcinoids, are rare and insidiously growing tumors. Related to their site of origin, tumors can be functional, causing various forms the carcinoid syndrome, owing overproduction serotonin, histamine, or other bioactive substances. They often invade adjacent structures metastasize liver elsewhere. Treatment includes multimodal approaches, cytoreductive surgery, locoregional embolization, cytotoxic therapy, peptide receptor radionuclide targeted therapies with goals symptom relief control tumor growth. This article summarizes current emerging approaches management reviews several promising future therapies.

参考文章(125)
C G Moertel, J A Hanley, Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer clinical trials. ,vol. 2, pp. 327- 334 ,(1979)
Jonathan R. Strosberg, Junsung Choi, Alan B. Cantor, Larry K. Kvols, Selective Hepatic Artery Embolization for Treatment of Patients With Metastatic Carcinoid and Pancreatic Endocrine Tumors Cancer Control. ,vol. 13, pp. 72- 78 ,(2006) , 10.1177/107327480601300110
Eric H. Liu, Carmen C. Solorzano, Laurence Katznelson, Aaron I. Vinik, Richard Wong, Gregory Randolph, AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoids. Endocrine Practice. ,vol. 21, pp. 534- 545 ,(2015) , 10.4158/EP14464.DSC
Kristen Massimino, Ola Harrskog, SuEllen Pommier, Rodney Pommier, Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients. Journal of Surgical Oncology. ,vol. 107, pp. 842- 846 ,(2013) , 10.1002/JSO.23323
P F Engstrom, P T Lavin, C G Moertel, E Folsch, H O Douglass, Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology. ,vol. 2, pp. 1255- 1259 ,(1984) , 10.1200/JCO.1984.2.11.1255
Edward Wolin, Barbara Jarzab, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael A. Morse, Paola Tomassetti, Matthias M. Weber, David Fogelman, John Ramage, Donald Poon, Brian Gadbaw, Jiang Li, Janice L. Pasieka, Abakar Mahamat, Fredrik Swahn, John Newell-Price, Wasat Mansoor, Kjell Öberg, Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues Drug Design Development and Therapy. ,vol. 9, pp. 5075- 5086 ,(2015) , 10.2147/DDDT.S84177
C. Waldherr, M. Pless, H.R. Maecke, A. Haldemann, J. Mueller-Brand, The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Annals of Oncology. ,vol. 12, pp. 941- 945 ,(2001) , 10.1023/A:1011160913619
M. Lesurtel, C. Soll, R. Graf, P.-A. Clavien, Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives. Cellular and Molecular Life Sciences. ,vol. 65, pp. 940- 952 ,(2008) , 10.1007/S00018-007-7377-3
M. Kroigaard, L. H. Garvey, L. Gillberg, S. G. O. Johansson, H. Mosbech, E. Florvaag, T. Harboe, L. I. Eriksson, G. Dahlgren, H. Seeman-Lodding, R. Takala, M. Wattwil, G. Hirlekar, B. Dahlén, A. B. Guttormsen, Scandinavian Clinical Practice Guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia Acta Anaesthesiologica Scandinavica. ,vol. 51, pp. 655- 670 ,(2007) , 10.1111/J.1399-6576.2007.01313.X
Lowell Anthony, Pamela U. Freda, From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Current Medical Research and Opinion. ,vol. 25, pp. 2989- 2999 ,(2009) , 10.1185/03007990903328959